Drug intelligence / Profile preview

docetaxel + irinotecan + lenograstim

Development stage: Unknown
Lead developer: Sanofi
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

This is a combination chemotherapy regimen consisting of docetaxel (a taxane), irinotecan (a topoisomerase I inhibitor), and lenograstim (a granulocyte colony-stimulating factor, G-CSF). The combination is used in oncology to treat certain advanced or refractory cancers, leveraging the cytotoxic effects of docetaxel and irinotecan with supportive care from lenograstim to reduce neutropenia risk. Docetaxel stabilizes microtubules, inhibiting cell division; irinotecan inhibits topoisomerase I, causing DNA damage; and lenograstim stimulates neutrophil production to counteract chemotherapy-induced neutropenia[1][2][6].

Other names: docetaxel/irinotecan/lenograstimdocetaxel plus irinotecan plus lenograstim

Targets

TUBB (Tubulin (alpha and beta subunits))CSF3R (Granulocyte colony-stimulating factor receptor)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on docetaxel + irinotecan + lenograstim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + irinotecan + lenograstim.

Explore the full profile